2019 international clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer
Venous thromboembolism (VTE) is the second leading cause of death in patients with
cancer. These patients are at a high risk of VTE recurrence and bleeding during …
cancer. These patients are at a high risk of VTE recurrence and bleeding during …
[引用][C] 2019 international clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer
D Farge, C Frere, JM Connors, C Ay, AA Khorana… - The Lancet …, 2019 - cir.nii.ac.jp
[PDF][PDF] 2019 international clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer
D Farge, C Frere, JM Connors, C Ay… - Lancet …, 2019 - thebloodproject.com
Venous thromboembolism (VTE) is the second leading cause of death in patients with
cancer. These patients are at a high risk of VTE recurrence and bleeding during …
cancer. These patients are at a high risk of VTE recurrence and bleeding during …
2019 international clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer.
D Farge, C Frere, JM Connors, C Ay… - The Lancet …, 2019 - folia.unifr.ch
English Venous thromboembolism (VTE) is the second leading cause of death in patients
with cancer. These patients are at a high risk of VTE recurrence and bleeding during …
with cancer. These patients are at a high risk of VTE recurrence and bleeding during …
2019 international clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer.
D Farge, C Frere, JM Connors, C Ay… - The Lancet …, 2019 - europepmc.org
Venous thromboembolism (VTE) is the second leading cause of death in patients with
cancer. These patients are at a high risk of VTE recurrence and bleeding during …
cancer. These patients are at a high risk of VTE recurrence and bleeding during …
[引用][C] 2019 international clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer
D Farge, C Frere, JM Connors, C Ay, AA Khorana… - The Lancet …, 2019 - elibrary.ru
2019 international clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer.
D Farge, C Frere, JM Connors, C Ay, AA Khorana… - The Lancet …, 2019 - sonar.ch
English Venous thromboembolism (VTE) is the second leading cause of death in patients
with cancer. These patients are at a high risk of VTE recurrence and bleeding during …
with cancer. These patients are at a high risk of VTE recurrence and bleeding during …
2019 international clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer
D Farge, C Frère, J Connors, C Ay, A Khorana… - Lancet …, 2019 - hal.science
Venous thromboembolism (VTE) is the second leading cause of death in patients with
cancer. These patients are at a high risk of VTE recurrence and bleeding during …
cancer. These patients are at a high risk of VTE recurrence and bleeding during …
2019 international clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer
D Farge, C Frere, JM Connors, C Ay… - THE LANCET …, 2019 - irinsubria.uninsubria.it
Venous thromboembolism (VTE) is the second leading cause of death in patients with
cancer. These patients are at a high risk of VTE recurrence and bleeding during …
cancer. These patients are at a high risk of VTE recurrence and bleeding during …
2019 international clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer
D Farge, C Frere, JM Connors, C Ay… - The lancet …, 2019 - scholarship.miami.edu
Venous thromboembolism (VTE) is the second leading cause of death in patients with
cancer. These patients are at a high risk of VTE recurrence and bleeding during …
cancer. These patients are at a high risk of VTE recurrence and bleeding during …